The absence of labeling for dysferlin and the rod domain and C-terminus of dystrophin in FFPE sections was documented in all three DMD patients (patients 4, 6, and 8) and the dysferlinopathy patient (patient 3) (Fig. 4), allowing a diagnosis to be made using FFPE sections. This evidence concerns the gene DMD and neuromuscular disease caused by qualitative or quantitative defects of dysferlin.